J&J, GSK unveil first detailed Phase III sirukumab data

Johnson & Johnson (NYSE:JNJ) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said sirukumab ( CNTO 136) met the co-primary endpoints in the Phase III SIRROUND-D study to treat moderately to severely active rheumatoid arthritis. The partners plan to submit global regulatory applications in 3Q16 for the human IgG1 kappa mAb against IL-6.

In December, GSK said sirukumab produced "positive" top-line results in three Phase III studies, but did not disclose details. J&J plans to present data from the other studies this year, according to spokesperson Brian Kenney (see BioCentury Extra, Dec. 16, 2015). ...